Treatment of fibrotic disease
View Patent ↗The invention relates to the use of INSP035 for treatment and/or prevention of fibrotic diseases, in particular of scleroderma.
1. A method for treating a fibrotic disease comprising administering to a patient having a fibrotic disease a therapeutically effective amount of a composition comprising a pharmaceutically acceptable carrier and a polypeptide comprising SEQ ID NO: 2, SEQ ID NO: 5 or SEQ ID NO: 7, wherein said fibrotic disease is lung fibrosis or liver fibrosis.
2. The method according to claim 1 , wherein the fibrotic disease is lung fibrosis.
3. The method according to claim 1 , wherein the polypeptide is glycosylated at one or more sites.
4. The method according to claim 1 , wherein the polypeptide comprising SEQ ID NO: 2 is a fusion protein.
5. The method according to claim 4 , wherein the fusion protein comprises an immunoglobulin Fc region fused to SEQ ID NO: 2.
6. The method according to claim 1 , wherein the polypeptide consists of SEQ ID NO: 2.
7. The method according to claim 1 , wherein the composition further comprises an interferon.
8. The method according to claim 7 , wherein the interferon is interferon-β.
9. The method according to claim 1 , wherein a composition comprising an interferon is administered to said patient simultaneously, sequentially, or separately with a composition comprising a pharmaceutically acceptable carrier and SEQ ID NO: 2.
10. The method according to claim 1 , wherein said fibrotic disease is liver fibrosis.
11. The method according to claim 1 , wherein said composition comprises a pharmaceutically acceptable carrier and a polypeptide comprising SEQ ID NO: 2.
12. The method according to claim 1 , wherein said composition comprises a pharmaceutically acceptable carrier and a salt of a polypeptide comprising SEQ ID NO: 2.
13. The method according to claim 12 , wherein said salt is a sodium, calcium, ammonium, ferric or zinc salt.
14. The method according to claim 12 , wherein said salt is a triethanolamine, arginine, lysine, piperidine or procaine salt.
15. The method according to claim 12 , wherein said salt is an acid addition salt.
16. The method according to claim 15 , wherein said acid addition salt is formed by the addition of hydrochloric, sulfuric, acetic or oxalic acid.
17. The method according to claim 1 , wherein said polypeptide comprising SEQ ID NO: 5 is a fusion protein.
18. The method according to claim 17 , wherein the fusion protein comprises an immunoglobulin Fc region fused to SEQ ID NO: 5.
19. The method according to claim 1 , wherein the polypeptide consists of SEQ ID NO: 5.
20. The method according to claim 1 , wherein said polypeptidc comprising SEQ ID NO: 7 is a fusion protein.
21. The method according to claim 17 , wherein the fusion protein comprises an immunoglobulin Fc region fused to SEQ ID NO: 7.
22. The method according to claim 1 , wherein the polypeptide consists of SEQ ID NO: 7.
23. The method according to claim 1 , wherein a composition comprising an interferon is administered to said patient simultaneously, sequentially, or separately with a composition comprising a pharmaceutically acceptable carrier and SEQ ID NO: 5.
24. The method according to claim 1 , wherein a composition comprising an interferon is administered to said patient simultaneously, sequentially, or separately with a composition comprising a pharmaceutically acceptable carrier and SEQ ID NO: 7.
25. The method according to claim 1 , wherein said composition comprises a pharmaceutically acceptable carrier and a polypeptide comprising SEQ ID NO: 5.
26. The method according to claim 1 , wherein said composition comprises a pharmaceutically acceptable carrier and a polypeptide comprising SEQ ID NO: 7.
27. The method according to claim 1 , wherein said composition comprises a pharmaceutically acceptable carrier and a salt of a polypeptide comprising SEQ ID NO: 5.
28. The method according to claim 27 , wherein said salt is a sodium, calcium, ammonium, ferric or zinc salt.
29. The method according to claim 27 , wherein said salt is a triethanolamine, arginine, lysine, piperidine or procaine salt.
30. The method according to claim 27 , wherein said salt is an acid addition salt.
31. The method according to claim 30 , wherein said acid addition salt is formed by the addition of hydrochloric, sulfuric, acetic or oxalic acid.
32. The method according to claim 1 , wherein said composition comprises a pharmaceutically acceptable carrier and a salt of a polypeptide comprising SEQ ID NO: 7.
33. The method according to claim 32 , wherein said salt is a sodium, calcium, ammonium, ferric or zinc salt.
34. The method according to claim 32 , wherein said salt is a triethanolamine, arginine, lysine, piperidine or procaine salt.
35. The method according to claim 32 , wherein said salt is an acid addition salt.
36. The method according to claim 35 , wherein said acid addition salt is formed by the addition of hydrochloric, sulfuric, acetic or oxalic acid.